Prepubertal exposure to zearalenone or genistein reduces mammary tumorigenesis by Hilakivi-Clarke, L et al.
Asian populations with a high intake of phyto-oestrogens have a
relatively low incidence of breast cancer (Setchell et al, 1984).
Therefore, it has been suggested that phyto-oestrogens may reduce
breast cancer risk (Messina et al, 1994). Phyto-oestrogens are
naturally occurring compounds produced by a variety of plants.
They are present in several foods, including soybean-based prod-
ucts that are typical for diets of Asia, but not for Western countries.
Approximately 50% of the isoflavones in soybeans consists of
genistein (Messina et al, 1994). There is some epidemiological
evidence in favour of soy/genistein being anti-tumorigenic, but
this is controversial. In three of a total of eight studies, a statisti-
cally significant association between high soy intake and low
breast cancer risk has been found (Nomura et al, 1978; Hirohata
et al, 1985; Lee et al, 1991; Yuan et al, 1995; Wu et al, 1996; Witte
et al, 1997; Zheng et al, 1999). While most animal studies are
supportive of the hypothesis that genistein inhibits mammary
tumour promotion (Hawrylewicz et al, 1991; Messina et al, 1994;
Barnes, 1997; Gotoh et al, 1998), some studies show an ability of
genistein to increase mammary tumorigenesis (Hsieh et al, 1998).
Prepubertal exposure via injections to a pharmacological dose of
genistein (500 mg kg–1) on days 16, 18 and 20 is reported to
dramatically reduce subsequent risk to develop mammary tumours
(Murrill et al, 1996). Thus, genistein may be particularly effective
in reducing breast cancer risk, if its exposure occurs prior to
puberty.
Zearalenone is another phyto-oestrogen that may be linked to
mammary tumorigenesis. Zearalenone is mainly produced by the
mould Fusarium graminearum found in a variety of host plants
and debris from soil around the world (Burgess et al, 1982). It is
present as a contaminant in stored cereals, being found in barley,
corn, corn flakes, rice and wheat at concentrations from 35 to 115
mg kg–1 (Hagler et al, 1984; Schoental, 1985; Luo et al, 1990).
Zearalenone also is used as an anabolic agent to enhance growth in
cattle and lambs (Ralston, 1978; Wiggins et al, 1979). In contrast
to genistein, pharmacological doses (10 mg kg–1 body weight) of
zearalenone have been associated with an increased breast cancer
risk in rats (Schoental, 1974).
Enthusiasm concerning the effects of prepubertal genistein
exposure is limited because the dose used in previous studies is
5000 times higher than that of human exposure on a mg kg–1 body
weight basis (Murrill et al, 1996). This pharmacological exposure
causes severe perturbations in hypothalamic-ovarian function
(Murrill et al, 1996) that may lead to infertility. Asians consume
2–9 g soy protein daily, while most women in Western countries
do not consume any soy (Seow et al, 1998; Wu et al, 1998).
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Summary Prepubertal exposure to a pharmacological dose (500 mg kg–1) of the phyto-oestrogen genistein can reduce the incidence and
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hypothalamic–pituitary–gonadal axis, making it unsuitable for breast cancer prevention. We studied whether prepubertal exposure to
genistein at a total body dose broadly comparable to the level typical of Oriental countries, approximately 1 mg kg–1 body weight, affects
mammary tumorigenesis. We also studied whether prepubertal exposure to zearalenone, a major source for phyto-oestrogens in the USA,
influences breast cancer risk. Prepubertal rats were treated between postnatal days 7 and 20, with 20 mg (~ 1 mg kg–1 body weight) of either
genistein or zearalenone. Zearalenone exposure significantly reduced both the incidence and multiplicity of mammary tumours induced by
7,12-dimethylbenz(a)anthracene (DMBA). Genistein exposure significantly reduced tumour multiplicity, but not tumour incidence, when
compared with vehicle-treated animals. Furthermore, 60% of the tumours in the genistein group were not malignant, while all the tumours
analysed for histopathology in the vehicle and zearalenone groups were adenocarcinomas. A higher number of differentiated alveolar buds,
and lower number of terminal ducts, were present in the DMBA-treated mammary glands of the phyto-oestrogen exposed rats. The
concentration of oestrogen receptor (ER) binding sites after the DMBA treatment was low in the mammary glands of all groups but a
significantly higher proportion of the glands in the zearalenone exposed rats were ER-positive (i.e. ER levels ³ 5 fmol mg–1 protein) than the
glands of the vehicle controls. Our data suggest that a prepubertal exposure to a low dose of either zearalenone or genistein may protect the
mammary gland from carcinogen-induced malignant transformation, possibly by increasing differentiation of the mammary epithelial tree.
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Genistein content of different soy products varies considerably;
for example, soy beans, soy milk and tofu contain approximately
2–18 mg genistein per g product, while miso and natto contain
40–330 mg genistein per g product (Lu et al, 1995; Fukutake et al,
1996). Fukutake et al (1996) have estimated that the daily
genistein intake is 1.5–4.1 mg (< 0.1 mg kg–1) among Asians.
Zearalenone is the main phyto-oestrogen consumed in the USA
(Kuiper-Goodman, 1990). The present study examined whether a
prepubertal exposure to a more physiological dose of genistein and
zearalenone (~ 1 mg kg–1 body weight) alters carcinogen-induced
mammary tumorigenesis in rats. In addition, we investigated
whether the concentrations of total oestrogen receptor (ER)
binding sites are altered by prepubertal phyto-oestrogen adminis-
tration. Low doses of genistein and zearalenone are known to bind
to ER and affect its transcriptional regulatory activities (Wang
et al, 1996; Collins et al, 1997; Zava and Duwe, 1997). The effect
on mammary gland morphology also was studied, since a previous
report suggested that an increased differentiation of the mammary
epithelial tree by prepubertal genistein exposure may explain its
cancer-reducing effects (Murrill et al, 1996).
METHODS
Animals
Pregnant female Sprague-Dawley rats, purchased from Charles
Rivers Breeding Laboratories, were obtained at day 10 of gesta-
tion. The animals were housed singly, in standard rat plexiglas
cages, at a constant temperature (20–22°C) and humidity
(60–65%), under a 12-h light–dark cycle (lights on 06:00 h). Two
days after the offspring were born, the males were sacrificed and
the females cross-fostered. Ten to twelve female pups were housed
with a lactating dam. The female offspring were weaned on
postnatal day 22, and thereafter housed in groups of 3–5 animals.
All studies were performed in accordance with the appropriate
institutional and federal requirements.
Phyto-oestrogen exposure
On postnatal day 7, the litters were divided into three groups. The
offspring received 20 mg genistein, 20 mg zearalenone (both from
Sigma Chemical Co., St Louis, MO, USA), or vehicle, adminis-
tered as subcutaneous injections, in a volume of 0.05 ml. Phyto-
oestrogens were first dissolved in 2% dimethyl sulphoxide
(DMSO), and then mixed with peanut oil (this mixture also served
as vehicle). The injections were repeated on days 10, 14, 17 and
20. Body weight of a rat pup on day 7 is approximately 10 g and
on day 20 25–30 g. Thus, the animals received genistein at the
doses ranging from 2 mg kg–1 (day 7) to 0.7 mg kg–1 (day 20).
Inducing and monitoring of mammary tumorigenesis
Mammary tumors were induced by administration of 10 mg (~ 50
mg kg–1 body weight) 7,12-dimethylbenz(a)anthracene (DMBA)
(Sigma, St Louis, MO, USA). This is a suboptimal dose used in
our laboratory to enable assessments of both reductions and
increases in the end points of tumorigenicity (Hilakivi-Clarke et al,
1997b). More than 75% of the tumours induced by 10 mg DMBA
are adenocarcinomas (Russo and Russo, 1987). The carcinogen
was dissolved in peanut oil and administered by oral gavage in a
volume of 1 ml. Animals were 45 days old at the time of DMBA
administration. The groups that were given phyto-oestrogens or
vehicle after birth each contained 30 animals.
The animals were examined regularly for mammary tumours by
palpation once per week. The end points for data analysis were
(i) latency to tumour appearance, (ii) the number of animals with
tumours (tumour incidence), (iii) the number of tumours per
animal (tumour multiplicity), and (iv) tumour proliferation. A
tumour was designated as proliferating if it increased regularly
in size. Tumour sizes were measured by recording the tumour
diameters with a caliper and determining the length of the longest
axis and the width perpendicular to the longest axis. The animals
were sacrificed when detectable tumour burden approximated
10% of total body weight, as required by our institution. All
surviving animals, including those that did not appear to develop
mammary tumours, were sacrificed 19 weeks after carcinogen
administration.
Histopathology of the DMBA-induced mammary tumours was
evaluated from 22 haematoxylin and eosin stained samples. Two
pathologists at the Lombardi Cancer Center (Georgetown
University) independently assessed the tumour samples. The
pathologists were blind to the experimental groups.
Oestrogen receptor
The number of ER binding sites in the 4th mammary glands were
determined from female rats exposed to genistein, zearalenone, or
vehicle during the prepubertal period (n = 7 per group). The
animals from which the mammary glands were taken had been
treated with DMBA 18 weeks before, and consequently developed
at least one mammary tumour. None of the tumours were in the 4th
gland in the animals used for ER assays. ERs were detected using
a ligand binding assay as described by Nelson et al (1986). The
ligand used was [2,4,6,7-3H] 17b oestradiol (specific activity 99
Ci mmol–1; Amersham, Arlington Heights, IL, USA). This assay
detects both ERa and ERb with equal efficacy. Thus, ER binding
reflects total ER concentrations (ERa + ERb).
Mammary gland morphology
Whole mounts of the 9th mammary glands of the same female rats
whose 4th glands were used for ER assays, were prepared (n = 4–5
per group). At the time of sacrifice, 18 weeks had passed from the
DMBA administration. The removed glands were stained with
carmine aluminium as previously described by Haslam (1988). We
have previously validated a visual scale to study the development
of a mouse and rat mammary epithelial tree (Hilakivi-Clarke et al,
1997a, 1997b). Using this scale, we determined differentiation of
mammary epithelial structures in the whole mounts. The
mammary epithelial trees were analysed for the density of ductal
structures, terminal ducts and differentiated alveolar buds. This
analysis was done double-blind under an Olympus dissecting
microscope, using a 5-point scale (from 0 = absent to 5 =
numerous). Differentiated alveolar buds do not give rise to adeno-
carcinomas. While terminal ducts occasionally give rise to
tumours, the majority of tumours originate from terminal end buds
(Russo and Russo, 1987). However, at the time the whole mounts
were obtained from 6-month-old rats, all terminal end buds had
differentiated to alveolar buds or regressed to terminal ducts. In
addition to this quantitative analysis of the mammary whole
mounts, a qualitative evaluation was performed.1684 L Hilakivi-Clarke et al
British Journal of Cancer (1999) 80(11), 1682–1688 © 1999 Cancer Research Campaign
Statistical analyses
Results for the data obtained on weight gain, ER binding sites,
density of epithelial ducts, terminal ducts and alveolar buds in the
whole mounts, and tumour latency, multiplicity, size upon first
detection and growth data were analysed using one-way analysis
of variance (Snedecor, 1988; Hanfelt, 1997). Where appropriate,
between-group comparisons were done using Fisher’s least signif-
icant difference. Results of tumour incidence were analysed using
a log-rank survival analysis test. Differences in the number of non-
proliferating and proliferating tumours, and the percentage of
mammary glands that contained ER levels that were either ³ 5
fmol mg–1 protein or < 5 fmol mg–1 protein, were determined using
a  c2 test. All probabilities are two-tailed. Statistical tests were
performed using the BMDP software (BMDP Statistical Software,
Los Angeles, CA, USA).
RESULTS
Effect on weight gain
Early postnatal exposure to either genistein or zearalenone did not
affect body weight gain. Between the first (day 7) and last day of
phyto-oestrogen exposure (day 21), weight increased by 2.5-fold
in the vehicle-treated rats, by 2.5-fold in the genistein-treated rats
and by 2.6-fold in the zearalenone-treated rats. Body weights also
were similar at the time the carcinogen was administered or 18
weeks after the administration (data not shown).
Mammary tumorigenesis
Tumour latency
The first tumours appeared on week 7 after the DMBA exposure in
all groups. The mean tumour latency time to the first tumour per
animal was significantly longer in the female rats exposed to zear-
alenone during early postnatal period than in the vehicle-treated
rats (F(2,37) = 4.91, P < 0.01) (Table 1). Tumour latency was
similar in the rats exposed to genistein or vehicle during prepu-
berty.
Tumour incidence
The incidence of mammary tumours (number of animals with
tumours per group) was determined weekly, beginning on week 7
following DMBA administration. At the end of the study, on week
18 following DMBA administration, the percentage of rats with
mammary tumours was 57% (17/30) in the vehicle-treated group,
43% (13/30) in the genistein-treated group, and 30% (9/30) in
the zearalenone-treated group (c2 = 14.92, df = 2, P < 0.001).
Log-rank test analysis indicated that the tumour incidence was
significantly lower in the animals exposed to zearalenone during
the prepubertal period than in the vehicle-treated controls (z-value
= 2.36, P < 0.018). The slightly lower tumour incidence in the
genistein-exposed rats was not statistically significant, when
compared with the controls (z = 1.03, P < 0.30) (Figure 1).
Tumour multiplicity
The average number of tumours per animal was significantly
lower in the rats exposed to genistein (P < 0.01) during prepubertal
life than in the vehicle-treated rats (F(2,38) = 4.53, P < 0.02).
A reduction that approached statistical significance also was seen
in the zearalenone-exposed rats (P < 0.06) (Table 1).
Tumour growth rate
The size of the tumours upon first detection was similar among the
groups (Table 1). However, the percentage of proliferating
tumours in the genistein- (60%) and zearalenone-exposed rats
(62%) was significantly lower than in the vehicle-treated group
(94%) (c2 = 9.96, df = 2, P < 0.001).
Tumour histopathology
Histopathological analysis performed for 22 samples indicated
that the histotypes of all mammary tumours in the vehicle- and
zearalenone-treated groups were adenocarcinomas (100%). In the
Table 1 Effects of early postnatal exposure to 20 mg genistein or 20 mg zearalenone on mammary tumour growth
Tumour latency Tumour area Tumour multiplicity Number of non-proliferating
(weeks) (mm2) tumours
Vehicle (n = 33/17)d 11.0 ± 0.7 64.5 ± 13.5 1.8 ± 0.3 2 (6%)
Genistein (n = 15/13) 11.4 ± 0.3 67.7 ± 14.2 1.1 ± 0.1b 6 (40%)c
Zearalenone (n = 13/9) 14.4 ± 0.3b 58.7 ± 15.7 1.2 ± 0.1a 5 (38%)c
Significantly different from vehicle group: aP < 0.06, bP < 0.01, cP < 0.001. dn = Number of tumours/number of animals with tumours. Note: 60% of the tumours in
the genistein group are benign, while all tumours examined in the vehicle and zearalenone groups are malignant adenocarcinomas. Data represent the mean ±
s.e.m. of latency to tumour appearance, area of tumours at first detection, tumour multiplicity and percentage of non-proliferating tumours. Number of rats per
group = 30.
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Figure 1 The proportion of female rats exposed to 20 mg genistein, 20 mg
zearalenone, or vehicle during postnatal days 7, 10, 14, 17 and 20, that
developed DMBA-induced (administered on day 45) mammary tumours. The
number of animals per group was 30. Tumour incidence was significantly
lower in the zearalenone-treated rats (P < 0.001)Prepubertal phytooestrogen exposure and mammary tumorigenesis 1685
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genistein-treated group, 40% of the tumours were adenocarci-
nomas and 60% were non-malignant.
Oestrogen receptor
The concentrations of ER protein were determined in the
mammary glands in rats that were exposed to DMBA 18 weeks
prior to sacrifice. The ER levels were similar in the animals treated
with genistein (3.4 ± 1.4 fmol mg–1 protein) or zearalenone (4.3 ±
2.8 fmol mg–1 protein) during the prepubertal period, and did not
differ from that of the controls (3.9 ± 1.7 fmol mg–1 protein). The
total ER levels in the present study were lower than we have seen
in mice (Hilakivi-Clarke et al, 1998), but comparable to those seen
in rats exposed to carcinogens (Thordarson et al, 1995).
We also determined the percentage of mammary glands that had
ER levels higher than 5 fmol mg–1. Breast tumours containing ER
levels  ³ 5 fmol mg–1 protein are often considered ER-positive
(Clark and McGuire, 1988; Winstanley et al, 1991). Using this cut-
off point the data indicate that the proportion of ER-positive
glands was significantly higher in the zearalenone-treated group
(43%) than in the genistein- (14%) or vehicle-treated (28%)
groups (c2 = 17.80, df = 2, P < 0.01).
Mammary whole mounts
Analysis of mammary whole mounts obtained from animals that
had been exposed to DMBA 18 weeks prior to sacrifice, indicated
that prepubertal exposure to genistein and zearalenone induced
distinct differences, when compared with the vehicle-controls
(Figure 2). The mammary glands of genistein-treated animals
showed the most lobular differentiation. These lobules were of
type 2 and 3, indicating a high level of differentiation.
Zearalenone-treated glands also showed differentiated lobular
structures, although less than that seen in the genistein-treated
glands.
According to the scale-based quantitative evaluation, total
mammary epithelial density did not differ among the groups
(Figure 3). However, the density of terminal ducts was signifi-
cantly lower in the rats exposed to zearalenone (P < 0.05) or genis-
tein (P < 0.05) during the prepubertal period than in the vehicle
controls (F(2,11) = 8.30, P < 0.006). The density of alveolar buds,
in turn, was significantly higher in the genistein-treated group
(P < 0.05) than in the controls (F(2,11) = 3.44, P < 0.07).
AB C
Figure 2 Mammary wholemount preparations (carmine staining) of the 9th abdominal glands obtained from 6-month-old female rats exposed to vehicle (A) 20
mg genistein (B) or 20 mg zearalenone (C) during a prepubertal period, and to DMBA at the age of 45 days. This figure is representative of 4–5 specimens per
group. The wholemounts of the genistein group contained high levels of 2–3 type lobules, and the whole mounts of zearalenone group indicated ductal atrophy,
combined with higher level of lobular structures than seen in the vehicle group (but clearly less than in the genistein group). Magnification x 6.3
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Figure 3 Density of epithelial ducts, terminal ducts (TDs) and  differentiated
alveolar buds (ABs) of the 9th abdominal gland obtained from 6-month-old
female rats exposed to 20 mg genistein, 20 mg zearalenone, or vehicle during
a prepubertal period, and to DMBA at the age of 45 days
(n = 4–5 female rats per group). These parameters were evaluated using a
scoring system with scores ranging from 0 (absent) to 5 (high), as described
in Methods. Means ± s.e.m. are shown. Significantly different from the
vehicle group: *P < 0.051686 L Hilakivi-Clarke et al
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DISCUSSION
Despite the general perception that consumption of soy-based food
products protects from breast cancer, the supporting epidemiolog-
ical evidence is inconsistent. Three studies suggest that soy intake
is associated with lower breast cancer risk. A study in Singaporean
women found that high soy intake is associated with a lower breast
cancer risk among premenopausal, but not postmenopausal,
women (Lee et al, 1991). A study in Asian-American women
living in Los Angeles or Hawaii indicated that breast cancer risk
decreases with increasing frequency of intake of tofu (bean curd)
both in pre- and postmenopausal women (Wu et al, 1996). Finally,
a study that measured urinary excretion levels of phyto-oestrogens
reported that a high excretion of isoflavones (genistein was not
included) was associated with a substantial reduction in breast
cancer risk (Ingram et al, 1997). A similar, but more recent, study
did not find significant differences in urinary excretion levels of
daidzein or genistein between breast cancer cases and their
controls in Shanghai; however, total isoflavonoid levels were
lower in the cases (Zheng et al, 1999). Soy protein intake was
similar in these Shanghai women who were newly diagnosed with
breast cancer and randomly selected controls. Four other studies
also suggest that the risk of breast cancer is not associated with soy
consumption (Hirohata et al, 1985; Yuan et al, 1995; Witte et al,
1997). These significant inconsistencies may reflect differences in
the end points used for genistein intake (consumption of tofu,
miso, or serum isoflavone concentrations). It also is possible that
timing of genistein exposure might be critical.
Treatment during prepuberty, with a pharmacological dose of
genistein, has been suggested to reduce the subsequent risk to
develop breast cancer. Murrill et al (1996) found that a subcuta-
neous exposure of prepubertal rats on postnatal days 16, 18 and 20
to 500 mg kg–1 genistein significantly reduces mammary tumour
incidence and multiplicity. However, this dose is 500–5000 times
higher than human genistein intake, and may not be directly rele-
vant to human populations. We have used a genistein dose of
~1 mg kg–1 body weight, which should approximate the daily
genistein consumption in Asia on a mg kg–1 body weight basis. If
this dose is further adjusted for interspecies surface area differ-
ences (Freireich et al, 1966; Clarke, 1997), a human genistein
exposure equivalent to 0.143 mg kg–1 body weight is obtained,
comparable to the exposure to genistein alone in Oriental popula-
tions (~ 0.1 mg kg–1 body weight). Our data show that when the
rats were exposed to this substantially lower genistein dose
between postnatal days 7 and 20, they exhibited reduced
mammary tumour multiplicity, but no significant change in tumour
incidence. Additionally, a significant proportion of the tumours in
the genistein group did not proliferate, and 60% of them were not
malignant. Thus, prepubertal exposure to genistein not only
reduced the subsequent mammary tumour multiplicity, it also
reduced the likelihood that a tumour was malignant.
The lack of significance in the tumour incidence and latency in
the genistein-exposed rats in the present study, when compared
with the previous study (Murrill et al, 1996), is likely to be caused
by the use of a low versus high dose of genistein. Genistein
displays a convex dose–response curve for oestrogenic activity.
Low genistein doses stimulate ER, while higher doses inhibit this
receptor’s activity (Wang et al, 1996). Inhibition of ER by high
genistein doses may be due to inhibition of the tyrosine kinase
activity of the epidermal growth factor receptor (EGFR) (Akiyama
et al, 1987), which could lead to a reduced phosphorylation of ER.
Another means by which pharmacological doses of genistein may
affect tumorigenesis is by influencing the reproductive system.
The 500 mg kg–1 genistein administration to prepubertal rats
caused a permanent impairment of the hypothalamic–gonadal axis
(Murrill et al, 1996). It also has been reported that 1 mg genistein
(~ 100 mg kg–1) given to rat pups daily between postnatal days 1
and 10, significantly decreases pituitary responsiveness to
gonadotrophin releasing hormone (GnRH) (Faber and Hughes,
1991). A ten times lower genistein dose (100 mg » 10 mg kg–1) has
the opposite effect, increasing GnRH-induced secretion of
luteinizing hormone (Faber and Hughes, 1991). Thus, changes in
the magnitude of a genistein exposure may have opposing effects
on the reproductive system. We did not perform a detailed analysis
of the reproductive system functions, and therefore cannot exclude
the possibility that a low genistein dose (1 mg kg–1) disrupts repro-
ductive functions. However, we did not observe any differences in
the timing of the onset of sexual maturation with prepubertal expo-
sure to either genistein or zearalenone (not shown), which would
be one measure of altered reproductive function.
Zearalenone, when administered during the prepubertal period,
effectively reduced DMBA-induced mammary tumorigenesis in
female rats. Rats that received 20 mg (~ 1 mg kg–1) zearalenone
every 3–4 days between days 7 and 20, subsequently exhibited a
longer latency to tumour appearance, and had a lower tumour inci-
dence than the vehicle-treated controls. In addition, one-third of
the tumours did not proliferate. However, histopathological evalu-
ation indicated that all the assessed tumours in the zearalenone
group were malignant. These findings contrast with earlier data
obtained in rats showing that treatment on postnatal days 7 and 14
with 10 mg kg–1 zearalenone increases the incidence of sponta-
neous mammary tumours (Schoental, 1985). The opposite results
may be caused by the tenfold difference in the dose of zearalenone
used in the two studies. We also treated the rats with a carcinogen
and measured tumorigenesis within the following 18 weeks, while
in the other study spontaneously arising tumours appeared when
the animals were 2 years of age. These differences also may indi-
cate that prepubertal zearalenone exposure inhibits premenopausal
breast cancer (that is mimicked by DMBA), and stimulates the
growth of postmenopausal breast cancer (that is mimicked by
spontaneous tumours in older rats).
Both genistein and zearalenone act as relatively weak oestro-
gens. They stimulate the growth of human breast cancer cells in
vitro (Martin et al, 1978; Wang et al, 1996), and have similar
properties to oestradiol in rodent and human breast tissues
(Petrakis et al, 1996; Harding et al, 1997; Santell et al, 1997; Hsieh
et al, 1998; McMichael-Phillips et al, 1998). Since oestrogens are
thought to increase breast cancer risk (Clarke et al, 1992), it is
surprising that genistein or zearalenone in the present and previous
study (Murrill et al, 1996) reduced the incidence/multiplicity of
mammary tumours. Perhaps oestrogens have opposing effects on
breast cancer risk depending on the timing of exposure. In utero
exposure to oestrogens, or an exposure during the first week after
birth, increases the subsequent incidence of mammary tumours in
mice and rats (Bern et al, 1985; Lopez et al, 1988; Hilakivi-Clarke
et al, 1997b), and possibly also in humans (Ekbom et al, 1992;
Michels et al, 1996; Sanderson et al, 1996). However, prepubertal
or pubertal treatment with oestradiol reduces mammary tumorige-
nesis in rats (Nagasawa et al, 1974; Grubbs et al, 1985). An expo-
sure to oestrogens during adulthood increases breast cancer risk in
animals (Clarke et al, 1992; Russo et al, 1994), and perhaps in
humans (Grodstein et al, 1997). These differences may reflectPrepubertal phytooestrogen exposure and mammary tumorigenesis 1687
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changes in the responsiveness of the mammary gland to ER
oestrogens over time.
In the present study, phyto-oestrogen exposure occurred during
a prepubertal period when the mammary epithelial cells are
thought not to respond fully to oestrogens, e.g. oestrogens do not
cause epithelial cell proliferation or alter ER levels (Haslam,
1989). We did not find any evidence that the prepubertal exposure
to genistein or zearalenone permanently affected the levels of ER
in the mammary gland. However, the mammary glands of the zear-
alenone-treated rats were significantly more often ER-positive
(had ER levels ³ 5 fmol mg–1 protein) than those of the genistein
group. Our findings are consistent with the fact that ligands can
alter the number/function of a receptor when they are present, and
generally do not cause any persistent changes in receptor expres-
sion. One exception is an exposure that occurs during fetal life or
immediately after birth, which can produce a permanent change
(Verhoeven et al, 1982; Bern et al, 1985; Hilakivi-Clarke et al,
1998). However, since a prepubertal treatment with both a low
(interacts with ER) and high (interacts with ER and other targets)
dose of genistein or zearalenone reduces subsequent mammary
tumorigenesis, prepubertal ERs may be involved as mediators of
these effects.
Whether or not the effects we report are a direct consequence of
changes in oestrogen-regulated gene function, it seems highly
likely that the mechanism for prepubertal oestrogen exposure in
affecting breast cancer risk involves changes in the mammary
epithelial network. We have proposed that the increased number of
terminal end buds and their reduced differentiation to alveolar
buds, plays a critical role in increasing breast cancer risk following
a perinatal oestrogen exposure (Hilakivi-Clarke et al, 1997a).
Terminal end buds, and to a lesser degree terminal buds, are the
primary sites of carcinogen action in the mammary gland (Russo
and Russo, 1987). Consistent with this hypothesis, prepubertal
exposure to a pharmacological genistein dose increases differenti-
ation of terminal end buds at the time when DMBA is adminis-
tered (Murrill et al, 1996). In our study, a more physiological dose
of genistein also increased differentiated alveolar buds, when
determined 18 weeks after DMBA exposure.
In summary, prepubertal exposure to a low dose of genistein or
zearalenone reduces the risk to develop mammary tumours in rats.
The mediating mechanisms remain to be established, but are likely
to include changes in the differentiation of mammary epithelial
tree and may reflect events mediated through activation of the ER.
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